N/A
Completed N=45,061
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
Influenza · Vaccination · Health Promotion · Health Behavior
Source: ClinicalTrials.gov NCT05009251 ↗
Enrolled (actual)
45,061
Serious AEs
—
Results posted
Jan 2023
Primary outcomePrimary: Flu Vaccination at 2 Weeks After Final Outreach Date — 5798; 5715; 5560; 5583 Participants — p=.054
Summary
The study team previously demonstrated that patients are more likely to receive flu vaccine after learning that they are at high risk for flu complications. Building on this past work, the present study will explore whether providing reasons that patients are considered high risk for flu complications (a) further increases the likelihood they will receive flu vaccine and (b) decreases the likelihood that they receive diagnoses of flu and/or flu-like symptoms in the ensuing flu season. It will also examine whether informing patients that their high-risk status was determined by analyzing their medical records or by an artificial intelligence (AI) / machine-learning (ML) algorithm analyzing their medical records will affect the likelihood of receiving the flu vaccine or diagnoses of flu and/or flu-like symptoms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Flu Vaccination at 2 Weeks After Final Outreach Date |
5798; 5715; 5560; 5583; 5662; 2668 | .054 |
| SECONDARY Flu Vaccination at 9 Weeks After Final Outreach Date |
5180; 5093; 4973; 4935; 5076; 3286 | — |
| SECONDARY Flu Diagnosis |
8336; 8382; 8365; 8346; 8385; 130 | — |
| SECONDARY Flu Complications |
5916; 5904; 5910; 5861; 5853; 2550 | — |
| SECONDARY Healthcare Utilization |
5203; 5221; 5205; 5160; 5311; 3263 | — |
Eligibility Criteria
Inclusion Criteria
- Aged 18 or older
- Current Geisinger patient at the time of study
- Falls in the top 10% of patients at highest risk, as identified by the flu-complication risk scores of machine learning algorithm (which operates on coded EHR data)
Exclusion Criteria
- Has contraindications for flu vaccination
- Has opted out of receiving communications from Geisinger via all of the modalities being tested
Data sourced from ClinicalTrials.gov (NCT05009251). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.